Brief: ADC Therapeutics Announces Positive Initial Data From Lotis-7 Clinical Trial Evaluating Zynlonta® In Combination With Bispecific
11/12/2024 13:32
Dec 11 (Reuters) - ADC Therapeutics ADCT.N :
* ADC THERAPEUTICS ANNOUNCES POSITIVE INITIAL DATA FROM
LOTIS-7
CLINICAL TRIAL EVALUATING ZYNLONTA® IN COMBINATION WITH
BISPECIFIC ANTIBODY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE
LARGE B-CELL LYMPHOMA
* ADC THERAPEUTICS SA - ZYNLONTA PLUS GLOFITAMAB SHOWS 94%
ORR AND
72% CR RATE
* ADC THERAPEUTICS SA - NO DOSE-LIMITING TOXICITIES OR
HIGH-GRADE
CRS/ICANS OBSERVED
Source text: ID:nPn7x6p8Ma
Further company coverage: ADCT.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adc Therapeutics
See all newsBrief: Adc Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements
ADC Therapeutics SA reports results for the quarter ended June 30 - Earnings Summary
ADC Therapeutics Q2 loss narrows; cuts 17% workforce
ADC Therapeutics SA expected to post a loss of 21 cents a share - Earnings Preview
ADC Therapeutics SA expected to post a loss of 21 cents a share - Earnings Preview